Royalty Pharma plc Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Royalty Pharma plc (RPRX) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $187.57 million as of 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Notes › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2025-02-12
- 2024-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $187.57M.
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $164.72M.
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $183.68M.
- 2021-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $203.93M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2024-12-31 | $187.57M 10-K · filed 2025-02-12 |
| 2023-12-31 | $164.72M 10-K · filed 2025-02-12 |
| 2022-12-31 | $183.68M 10-K · filed 2024-02-15 |
| 2021-12-31 | $203.93M 10-K · filed 2023-02-15 |
| 2020-12-31 | $183.42M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |